Abstracts | 41 diagnosis of PTSD. Finally, I will discuss aspects of the various trials that point to how NAC may be most effectively employed clinically in combination with psychosocial interventions, and perhaps other pharmacological treatments. 
Abstract
There has been a decline in new therapies for unipolar depression. Current pharmacological therapies are attributed to symptom remission in only 30% of individuals with unipolar depression. As such, there is a clear need for the development of new therapies, instigated by investigators rather than reliance on pharmaceutical companies.
There have been significant advancements in the understanding of the underlying pathophysiology of unipolar depression. Significant evidence is available to suggest that unipolar depression is mediated by inflammation. This is demonstrated by the induction of depressive symptoms following pro-inflammatory treatment (e.g. interferon in hepatitis-C) and more importantly, by alterations in peripheral cytokine levels in individuals with unipolar depression. Given this, we planned to trial a treatment specifically targeting inflammation as an adjunct to usual for individuals with moderate-severe unipolar depression. The agent selected is minocycline, a tetracycline antibiotic which has also been shown to inhibit microglial activation and also reduce oxidative stress, augment glutamate pathways and promote neuronal growth. This agent is of particular interest as in addition to increased inflammation, depression is also characterized by increased oxidative stress, altered glutamate function and decreased levels of neuronal growth factors (e.g. BDNF). We have completed a pilot double-blind placebo controlled trial of 200 mg/ day of minocycline as an adjunct to treatment as usual. The study includes 12 weeks of treatment followed by a followup visit 4 weeks later. The primary outcome measure for the study is the Montgomery Asberg Depression Rating Scale and a variety of clinical impression, functioning and quality of life scales are also included as secondary outcomes. The last study visit will be completed in December 2015 and trial results will be available in early 2016 to determine the preliminary efficacy of minocycline as an adjunctive therapy for moderate to severe unipolar depression.
Speaker 3: Felice Jacka, Australia
Title: Novel therapies for psychiatric disorders: from translation to implementation Abstract With depressive disorders the leading source of disability globally, the identification of new targets for prevention and management is imperative. A rapidly emerging field of research suggests that the microbiome-brain axis is of substantial relevance to mood and behavior. Similarly, unhealthy diet has recently emerged as a significant correlate of and risk factor for depression. This review provides evidence for the gut microbiota as a key factor mediating the link between diet and depressive illness and focuses on the potential of gut-focused interventions for the prevention and treatment of mood disorders. Recent findings: The development of new technologies is affording a better understanding of how diet influences gut microbiota composition and activity and how this may, in turn, influence depressive illness. New evidence is also pointing to the possible utility of pre and probiotic formulations and fermented food in influencing mental health. Summary: Although in its early stages, the emerging field of research focused on the human microbiome suggests an important role for the gut microbiota in influencing brain development, behavior and mood in humans. The recognition that the gut microbiota interacts bi-directionally with other environmental risk factors, such as diet and stress, suggests promise in the development of interventions targeting the gut microbiota for the prevention and treatment of common mental health disorders. Keywords: Microbiota, depression, diet, psychiatry, inflammation, prevention Abstract Introduction: Depression in bipolar disorder is complex to treat, with few efficacious agents. Bipolar disorder thus is a significant burden on individuals, caregivers and the broader community. Current treatments are generally more effective against manic than depressive symptoms. The current study capitalises on recent evidence that alterations in mitochondrial function occur in bipolar disorder. Since there are many agents that have actions on mitochondrial bioenergetics, that this may be a druggable target. Methods: This was a 3 arm 16-week study which aimed to explore the potential effects of placebo, N-acetylcysteine (NAC) alone or NAC in combination with a combination of agents believed to enhance mitochondrial function in addition to any usual treatments (acetyl-l-carnitine, ubiquinone, alpha tocopherol, magnesium, thiamine, riboflavin, nicotinamide, calcium pantothenate, pyridoxine, folic acid, cyanocobalamin, calcium ascorbate, retinyl palmitate, cholecalciferol, biotin). The study included adults with bipolar disorder currently in an episode of depression. A post-discontinuation visit was conducted 4 weeks following the treatment phase. Results: The primary outcome of the study was mean change on the Montgomery-Asberg Depression Rating Scale. Secondary outcomes included functioning, substance use, mania ratings, and quality of life. Conclusion: This study will firstly provide evidence as to whether a novel adjunctive treatment for bipolar depression targeting mitochondrial bioenergetics has efficacy for the depressive phase of the disorder, and will provide mechanistic support for the notion that there is a primary abnormality of mitochondrial bioenergetics in the disorder. Reasons for this discrepancy are related among others in the way guidelines are developed by the respective commissions: the experts are often not or not any more clinically experienced, the priority given to meta-analyses lead to relative global results, for more differentiated treatment problems (drug resistence, predominance of certain sub-syndromes, psychiatric and non-psychiatric comorbidity, co-medication etc.) Sufficient data are not available, individual dispositions of the patients are not sufficiently considered in the EBM data base, the gap between phase-studies and phase-4 studies is difficult to overcome.
S25: The
The current position of EBM neglects extremely the value of clinical practice and is not open enough for more critical reflections about is own methodological limitations. Especially the one-sided preference for meta-analyses should be replaced by a multi-methods approach, involving much more the evaluation of individual studies.This would help among others to give answers also to questions mentioned above, so far mostly not addressed sufficiently by the available guidelines.
Speaker 2: Konstantinos N Fountoulakis, Greece
Title: The Collegium International NeuroPsychopharmacologicum (CINP) treatment guidelines for bipolar disorder in adults Abstract The CINP assembled a workgroup to develop guidelines and a precise algorithm for Bipolar disorder (BD). The works are still in progress and the actual guideline is expected to be published within 2016. These guidelines will be based on hard data and were intented to be as evidence based as possible. A new system of grading the evidence was developed. Monotherapy was given priority over combination therapy. The first approach led to draft detailed guidance for each phase of BD in a five-step way, by taking into consideration the specific clinical features if possible. The second includes a very precise algorithm. When released, the CINP guidelines will be the most recent fully updated and fully evidence based guidelines on the treatment of BD. Many issues need further study, data are rare and insufficient and many questions remain unanswered. The most important and still unmet need is to be able to merge all the guidelines which concern different phases of the illness into a single one, and in this way consider BD as a single unified disorder, which is the real world fact. However todate the research data do not permit such a unified approach.
Speaker 3: Siegfried Kasper, Austria
Title: Evidence based treatment of refractory bipolar patients.
Abstract
Definition of refractory bipolar patients is based on the course of the illness as well as current and past psychopathological status. Different steps of treatment considerations are considered for acute mania, hypomania as well as acute bipolar depression and thereafter for treatment during the maintenance phase. The steps can be grouped by evidence based from 1 to 5 and also non recommended types of medication need to be considered. Specific patient populations include those with agitation, pregnancy, lactation and the use of oral contraceptives as well as the management of somatic problems in bipolar disorder. It is obvious that evidence based guidelines like the CINP guidelines are limited by the data that is available and need to be regularly updated.
Speaker 4: Lakshmi Yatham, Canada
How to incorporate the (CINP) algorithm into the everyday clinical
